KLOW peptide research: four component literatures, one honest record

Before the details

KLOW peptide is a blend of four separately-studied research compounds. The most important thing to know before reading the mechanism section is this: every study here is a single-component study. None measured the four-peptide combination. All claims about what the blend does in combination are mechanistic extrapolations — educated reasoning from four separate literatures, not direct experimental findings. This page sets out those four literatures accurately, with each finding attributed to its source compound. The gaps are marked in plain sight.

KPV: anti-inflammatory arm

KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (alpha-MSH, a 13-residue regulatory peptide). It is the anti-inflammatory arm of the KLOW stack.

Its primary studied mechanism is inhibition of NF-kappaB nuclear import — NF-kappaB (Nuclear Factor kappa B) is the transcription factor that, when active, switches on the genes encoding TNF-alpha, IL-6, IL-1beta and other pro-inflammatory signaling proteins. KPV has been shown to suppress NF-kappaB and MAP-kinase (MAPK) inflammatory signaling in human intestinal epithelial cells and Jurkat T cells in vitro, and to reduce pro-inflammatory cytokine secretion at nanomolar concentrations ^[3].

Its uptake is governed by PepT1 (SLC15A1), the intestinal di/tripeptide transporter that is upregulated in inflamed gut epithelium. KPV's Km for PepT1 is approximately 160 micromolar — meaning it is a substrate of the transporter at concentrations achievable in the inflamed mucosa. In DSS- and TNBS-induced colitis mouse models, oral KPV at 100 micromolar in drinking water reduced the severity of colitis ^[3].

No controlled KPV monotherapy trial has reached regulatory approval. Human data are restricted to delivery pilots and an IBD-lineage program.

GHK-Cu: skin-matrix and gene-expression arm

GHK-Cu (Gly-His-Lys copper complex, Copper Tripeptide-1) is the mass-dominant component — approximately 50 of 80 mg in the canonical vial, or 62.5% by mass. First isolated from human plasma by Loren Pickart in 1973, it is the best-studied component for skin-matrix effects.

Its broadest finding is transcriptomic: at low-nanomolar concentrations in cultured fibroblasts, GHK modulates approximately 31.2% of human protein-coding genes at a 50%-or-greater change threshold, increasing expression of 59% of affected genes and suppressing 41%, with the strongest upregulation signals on extracellular-matrix remodeling, antioxidant defense, DNA repair and protein-quality-control pathways ^[5]. The often-quoted '4,000 genes' figure is a rounding; the 50%-threshold table covers on the order of 2,100 genes.

In the skin-regeneration literature, GHK-Cu stimulates synthesis of collagen, dermatan sulfate, chondroitin sulfate and the proteoglycan decorin ^[4]. Plasma GHK levels decline from roughly 200 ng/mL at age 20 to roughly 80 ng/mL by age 60 ^[4]. In a placebo-controlled topical study, GHK-Cu increased collagen production in 70% of treated women versus 50% for vitamin C and 40% for retinoic acid ^[4]. A 2025 review synthesizes the anti-wrinkle evidence and the current understanding of GHK delivery challenges ^[11].

A 2024 mechanistic study adds a fibrosis angle: GHK reverses age-related fibrosis in cultured cells by modulating myofibroblast (scar-forming cell) function toward a more regenerative phenotype ^[12].

For hair: a 6-month placebo-controlled trial of 45 men with androgenetic alopecia found a topical formulation combining GHK with 5-aminolevulinic acid (ALAVAX) increased hair count by 52.6 at the higher dose and 71.5 at the lower dose versus 9.6 for placebo (p<0.05), with no adverse events ^[9]. This is the strongest controlled human efficacy signal for a GHK-containing topical, though the active formulation includes a second agent; the finding cannot be attributed to GHK alone.

A copper-tripeptide analog (AHK-Cu, the alanyl analog of GHK-Cu) at 10^-12 to 10^-9 M stimulated elongation of human hair follicles and proliferation of dermal papilla cells ex vivo, and reduced apoptosis ^[10]. This study tests AHK-Cu, not GHK-Cu; it provides analog-context evidence only.

GHK-Cu also supplies copper for lysyl oxidase, a copper-dependent enzyme that crosslinks collagen and elastin — a mechanistically direct link between the peptide's copper delivery and matrix integrity ^[4].

Human skin penetration data: copper applied as GHK-Cu tripeptide penetrated dermatomed skin with a permeability coefficient of 2.43 ± 0.51 × 10^-4 cm/h; 136.2 ± 17.5 μg/cm² permeated over 48 hours and 97 ± 6.6 μg/cm² was retained as a dermal depot ^[8]. This establishes topical delivery as a pharmacokinetically viable route.

BPC-157: angiogenic and tissue-repair arm

BPC-157 (Body Protection Compound 157, PL 14736) is a synthetic 15-amino-acid peptide (sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a protein isolated from human gastric juice. In KLOW it contributes 10 of the 80 mg.

Its primary studied mechanism is activation of the VEGFR2/PI3K/Akt/eNOS angiogenic axis — VEGFR2 (vascular endothelial growth factor receptor 2) is the principal receptor governing new blood-vessel formation; its downstream signaling through PI3K, Akt and eNOS drives endothelial cell proliferation and migration. BPC-157 also upregulates the growth-hormone receptor in tendon fibroblasts and modulates the nitric-oxide system in a manner partly resistant to L-NAME (a nitric-oxide synthesis inhibitor), suggesting an alternative NO route.

The rodent tissue-repair literature is extensive. In Wistar rats with a fully transected Achilles tendon, BPC-157 administered intraperitoneally at 10 μg, 10 ng or 10 pg per rat once daily accelerated healing across biomechanical, functional, microscopic and macroscopic measures, and stimulated tendocyte outgrowth in vitro ^[2].

Human data are limited. A 2025 first-in-human IV safety pilot reported that intravenous BPC-157 up to 20 mg in two healthy adults was well tolerated, with no observed adverse events and no measurable changes in cardiac, hepatic, renal, thyroid or glucose biomarkers ^[6]. This is a tiny n and not an efficacy trial. A 2024 pilot in interstitial cystitis patients reported complete symptom resolution in 10 of 12 participants and approximately 80% improvement in the remaining two, with a 5/5 Global Response Assessment and no adverse events ^[13] — an uncontrolled pilot; the finding warrants follow-up.

BPC-157 was placed by the FDA in category 2 of the 503A bulk-substances review (meaning it is not a candidate for compounding in standard office practice).

TB-500: cytoskeletal and wound-closure arm

TB-500 is a synthetic N-acetylated heptapeptide, Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (Ac-LKKTETQ), marketed as the actin-binding fragment of thymosin beta-4 (Tbeta4). It contributes 10 of the 80 mg in KLOW. An important disambiguation: most of the foundational efficacy evidence is for full-length native thymosin beta-4 (43 amino acids), not for the TB-500 fragment; the two are not interchangeable in the literature.

The LKKTET motif of thymosin beta-4 sequesters G-actin (globular, monomeric actin), holding it in a mobile reserve that cells draw on during migration and wound closure. Full-length Tbeta4 additionally activates integrin-linked kinase (ILK) and mobilizes epicardial progenitor cells — activities established for the native protein, not demonstrated for the TB-500 fragment.

In a rat full-thickness wound model, topical or intraperitoneal thymosin beta-4 increased re-epithelialization by 42% at 4 days and up to 61% at 7 days versus saline, increased wound contraction (at least 11% by day 7) and raised collagen deposition and angiogenesis; as little as 10 pg stimulated keratinocyte migration 2 to 3-fold ^[1]. These are native-Tbeta4 findings. A 2026 sports medicine review of unapproved musculoskeletal peptides (including TB-500 and thymosin beta-4) concludes that animal-model data are promising but rigorous human safety data are scarce ^[7].

TB-500 and thymosin beta-4 are prohibited at all times under the WADA Prohibited List (S2) — this applies to athletes in and out of competition ^[7].

What the combination claim rests on

The rationale for combining all four is that their mechanisms occupy non-overlapping nodes of one tissue-repair cascade: KPV handles cytokine suppression, GHK-Cu handles matrix remodeling, BPC-157 handles vascular supply and tendon repair, and TB-500 handles cytoskeletal mobility and re-epithelialization. In principle these are complementary.

In practice, three things complicate the claim. First, no study has tested the combination. Second, the pharmacokinetic profiles of the four components are mismatched — the tripeptides clear far faster than BPC-157, and the TB-500 fragment differs from native Tbeta4 — so a single co-formulated dose cannot keep all four at meaningful concentrations simultaneously. Third, some mechanisms overlap (GHK-Cu and BPC-157 are both pro-angiogenic; KPV and GHK-Cu both modulate inflammatory signaling), which could produce redundancy or, theoretically, uncharacterized interactions.

The KLOW references page lists every citation used across this site.